How Hantavirus Spreads: Causes, Risks, and Prevention

How Hantavirus Spreads

Understanding how hantavirus spreads is the first critical step in protecting yourself and your family from a rare but highly dangerous respiratory disease. Whether you are cleaning out an old barn, sweeping a dusty attic, or opening up a long-closed summer cabin, knowing the risks associated with rodent-borne pathogens can quite literally save your life. Hantaviruses are primarily excreted in the urine, droppings, and saliva of infected wild rodents, and most human infections occur when these substances are disturbed and become airborne, allowing microscopic viral particles to be easily inhaled.

Novo Nordisk Announces Positive Topline Results for Oral Semaglutide for Type 2 Diabetes in Children

novo nordisk

Novo Nordisk has announced breakthrough results from its PIONEER TEENS trial, proving that oral semaglutide for type 2 diabetes in children offers superior glycemic control and a well-tolerated safety profile for adolescents.

Lilly’s Foundayo orforglipron ACHIEVE-4 Study: Updated Safety Profile

Eli Lilly and Company

Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.

J&J’s ICOTYDE Icotrokinra Results Confirm Long-Term Skin Clearance in Psoriasis Patients

JohnsonAndJohnson

Johnson & Johnson has announced breakthrough one-year data for ICOTYDE (icotrokinra), demonstrating that the once-daily oral peptide maintains high rates of skin clearance and a favorable safety profile in patients with plaque psoriasis.

Novo Nordisk’s UBT251 Triple Agonist Achieves Landmark 2.16% HbA1c Reduction in Type 2 Diabetes Phase 2 Trial

novo nordisk

Novo Nordisk and United Biotechnology announce that their jointly developed UBT251 triple agonist targeting GLP-1, GIP, and glucagon receptors outperformed semaglutide 1 mg in a 24-week Chinese phase 2 trial, setting the stage for global phase 3 development.